Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Intro to Pharmacogenomics: Trying to Understand Differences in Treatment Outcomes
Author
Howard (Jack) West, MD

Infused throughout the website is a constant recognition that "patients are different", but while we know this intuitively, we're really not moved to a point of individualizing treatment on the basis of this. There are many lines of clinical research that are moving in that direction, and one of the key elements is pharmacogenomics, the study of the genetic underpinnings of the differences among people in response to a medication, both in terms of response and side effects. The slides for this post are stolen appropriated from Dr. David Gandara, one of the true leaders in the field of lung cancer, who heads the Lung Cancer Program at the University of California at Davis, as well as the Lung Cancer Committee for the Southwest Oncology Group (SWOG). He is also the new President Elect of the International Association for the Study of Lung Cancer. He and his collaborators have been adding to our understanding of this field as it relates to lung cancer.

Whether we're talking about conventional chemotherapy, EGFR inhibitors, or just narcotics, it's clear that there are major differences in how different patients respond. Although we're on the cusp of tailoring treatments based on type of NSCLC (squamous vs. adeno, or BAC, for instance), and smoking status, and perhaps even racial background, our general practice has historically been to use a one size fits all approach:

Pharmacogenetics all same

(Click on image to enlarge)

In fact, though, we know that some patients have a very nice response to chemo, or a targeted therapy like tarceva, while others have a minimal response or actually progress on treatment. We also know that some people tolerate chemo very well, while others terrible side effect problems. We could really improve the field if we could identify, using molecular profits, the best vs. the worst responders and the patients who were destined to develop terrible treatment side effects before we actually give the therapy:

Pharmacogenomics different groups

By doing that, we could separate out those patients who would have a poor response or bad toxicity and give them a different treatment instead:

Pharmacogenomics, diffs and separate

At the present time, we routinely use squamous vs. adenocarcinoma histology, as well as smoking status, for clinical decision-making, but these are clinical and not molecular profiles. We have several examples of molecular profiles that are very promising and are beginning to be employed but are not yet considered standard approaches for routine management. Examples include ERCC1 for assessing resistance to cisplatin (post here), gene signatures to predict which patients are responsive to various chemo agents (post here), EGFR FISH in predicting improved outcomes on cetuximab (post here), or resistance to EGFR inhibitors as predicted by ras mutations (post here).

Another potential implication of this work is that there may be important differences in how various treatments work in different populations. EGFR inhibitors may be considerably more effective in studies from Japan than ones from the US or Europe. Chemo may work differently in some populations than in others. But as more and more trials are done in Asia, Europe, and elsewhere around the world, the study of pharmacogenomics reminds us that it is important to consider whether we can generalize conclusions across continents and different races. We'll turn to such questions next.

Next Previous link

Previous PostNext Post

Related Content

Image
Trial data ASCO 2024
Video
In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO. To watch the complete playlist, click here.         
Image
Bladder Cancer Video Library 2024
Video
Dr. Petros Grivas discusses intravesical treatment for patients with nonmuscle invasive, or early-stage, bladder cancer, the importance of participating in clinical trials for bladder cancer, combination therapy options for patients with metastatic or incurable bladder cancer, and the importance of family history of cancer and discussing that history with your doctor.
Image
Case Based Panel
Video
The panel discusses treatment options for a patient diagnosed with EGFR Exon 19 Deletion NSCLC and examines data from the Laura Trial, a patient with a smoking history and diagnosis of small cell lung cancer, and how the Adriatic Study factors into decisions, and a patient with NSCLC adenocarcinoma, and a EGFR Exon 21 L858R Alteration, and how data from the Flaura 2 Trial can impact treatment decisions.

Forum Discussions

Hi elysianfields and welcome to Grace.  I'm sorry to hear about your father's progression. 

 

Unfortunately, lepto remains a difficult area to treat.  Recently FDA approved the combo Lazertinib and Amivantamab...

Hello Janine, thank you for your reply.

Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...

Hi elysianfields,

 

That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...

Recent Comments

JOIN THE CONVERSATION
That's beautiful Linda…
By JanineT GRACE … on
I could not find any info on…
By JanineT GRACE … on
Hi elysianfields,

 

That's…
By JanineT GRACE … on
Hello Janine, thank you for…
By elysianfields on